[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624159":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":13,"locations":10,"responsibleParty":22,"collaborators":10,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":28,"acronym":29,"eligibilityCriteria":30,"healthyVolunteers":31,"sex":32,"minAge":33,"maxAge":34,"enrollmentInfo":35,"targetDuration":10,"studyType":38,"phases":10,"briefSummary":39,"conditions":40,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":10},{"fullName":5,"class":6},"Central Hospital, Nancy, France","OTHER",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"Patient",null,{"label":12,"type":10,"description":10,"interventionNames":10},"Relative",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":10,"email":18},"Eva Feigerlova, MD, PhD, MMEd","CONTACT","+330383154796","e.feigerlova@chru-nancy.Fr",{"name":20,"role":16,"phone":17,"phoneExt":17,"email":21},"François Feillet, MD, PhD","f.feillet@chru-nancy.fr",{"type":23,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100624159","the-psychosocial-functioning-of-adults-with-phenylketonuria-100624159",false,"NCT07406009","The Psychosocial Functioning of Adults With Phenylketonuria.","CoMet-PCU","Inclusion Criteria:\n\nPatients :\n\n* Age ≥ 18 years and \\\u003C 59 years (age limit for ASEBA questionnaire)\n* Person being monitored for PKU \u002F HMP\n* Relative living with the person\n* Person who has received full information on the organization of the research and has not objected to the use of this data\n* Compulsory membership of a social security scheme\n\nRelatives:\n\n* Age ≥ 18 years\n* Person who has received full information on the organization of the research and has not objected to the use of this data\n* Compulsory membership of a social security scheme\n\nExclusion Criteria:\n\n* Refusal or linguistic, physical or psychological incapacity to to participate in the study\n* Subjects under court protection\n* Subjects under guardianship or curatorship",true,"ALL","18 Years","59 Years",{"count":36,"type":37},30,"ESTIMATED","OBSERVATIONAL","Current recommendations are to maintain Phe levels \\\u003C 360 µmol\u002FL throughout life (US consensus) or \\\u003C 600 µmol\u002FL from the age of 12 (European consensus). Nevertheless, these recommendations do not take into account the individuality of each PKU patient who, in reality, reacts differently to Phe levels, with some patients with high levels (\\> 1200 µmol\u002FL) escaping the neurological consequences of high Phe levels without this being well understood (OJRD 2018; 13: 149. Can untreated PKU patients escape from intellectual disability? A systematic review). It is therefore unclear what blood levels of phenylalanine are required during adolescence and adulthood to maintain an optimal cognitive, emotional and neurophysiological state in individual PKU patients, depending on their personal responsiveness to Phe.",[41],"Phenylketonuria (PKU)","NOT_YET_RECRUITING","2026-02-05",{"date":45,"type":46},"2026-02-12","ACTUAL",{"date":48,"type":37},"2026-01-15",{"date":50,"type":37},"2027-06-15",{"name":5,"class":6}]